Market revenue in 2024 | USD 557.8 million |
Market revenue in 2030 | USD 941.8 million |
Growth rate | 9.1% (CAGR from 2024 to 2030) |
Largest segment | Targeted therapy |
Fastest growing segment | Targeted Therapy |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Targeted Therapy, Immunotherapy |
Key market players worldwide | Roche Holding AG, AstraZeneca PLC ADR, Eli Lilly and Co, Bayer AG, Pfizer Inc, Bristol-Myers Squibb Co, Cadila Pharmaceuticals, Ono Pharmaceutical Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liver metastases treatment market will help companies and investors design strategic landscapes.
Targeted therapy was the largest segment with a revenue share of 56.79% in 2024. Horizon Databook has segmented the Europe liver metastases treatment market based on chemotherapy, targeted therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe liver metastases treatment market, including forecasts for subscribers. This continent databook contains high-level insights into Europe liver metastases treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account